NCT00093067View on ClinicalTrials.gov

Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2002

Primary Completion Date

November 30, 2004

Study Completion Date

February 28, 2005

Conditions
Bacterial EndocarditisBacteremia
Interventions
DRUG

daptomycin

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00093067 - Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus | Biotech Hunter | Biotech Hunter